Translating new discoveries into clinical applications: the BC Cancer Agency Research Centre investigates causes of cancer, advances in treatment and improvements in how we detect, manage and cure the disease.

How we serve the people of BC:

- The BC Cancer Agency is recognized internationally for its advancements in cancer research.
- Researchers are working to identify promising new therapies and to improve existing therapies by increasing their effectiveness and reducing side effects.
- Research discoveries move quickly from the laboratory bench to the patient’s bedside because researchers work closely with their clinical colleagues in all six regional cancer centres to quickly translate clinical research discoveries into new treatments and therapies.
- To explore more effective use of health care resources and improved ways of delivering care to a diverse population of patients across the province, researchers also work with physicians, scientists, research technicians and post-graduate students to study health economics and population-based research questions.

Funded by the BC Cancer Agency and the BC Cancer Foundation, there are eight research departments and divisions:

- Cancer Control Research
- Trev & Joyce Deeley Research Centre in Victoria
- Experimental Therapeutics
- Genome Sciences Centre
- Integrative Oncology
- Molecular Oncology
- Terry Fox Laboratory
- Lymphoid Cancer Research

It is focused on:

1. Expanding genomic sciences in support of personalized cancer care.
2. Improving knowledge of the causes of cancer and the strategies in prevention.
3. Leveraging discoveries through cancer research by enabling their translation into the clinical setting.
The BC Cancer Agency is recognized internationally for its advancements in cancer research:

- Dr. Stuart Peacock appointed the Leslie Diamond Chair in Survivorship—this $5 million endowment represents a significant partnership towards cancer survivorship between the BC Cancer Agency, Simon Fraser University and the BC Cancer Foundation
- Personalized oncogenomics program—in second phase of studies to sequence the DNA of individual patients for personalized cancer treatment
- Researchers develop a first-in-Canada technology to help specialists to better detect lung cancer. The new 3D navigation system enhances diagnosis, staging and care for patients
- Ovarian Cancer Research Program (OVCARE) (a partnership between the BC Cancer Agency, the University of British Columbia and the Vancouver Coastal Health Research Institute) experts first to implement surgical protocols that recommend the removal of women's Fallopian tubes during hysterectomies in order to reduce their risk of developing ovarian cancer
- BC Cancer Agency scientists decode the genetic make-up of triple negative breast cancer.
- The BC Cancer Agency and the University of British Columbia identify new breast cancer genes that could change how the disease is diagnosed and form the basis of next-generation treatments; the disease is reclassified into 10 completely new categories based on the genetic fingerprint of a tumour.

$75M
Approximately $75 million in funding through research grants ($65 million in funding through Canadian and International funders).

$10M
in funding from Canadian and Industry sponsored research.

71
faculty

670
research staff

2014/15